Observed Signal · Oct 13, 2026 · corporate_event · Source: SEC API · Impact: 4.1/5
8-K Financial Filing Analysis for Humana (2026-10-13)
On October 13, 2026, Humana Inc. announced a new joint venture arrangement with funds managed by HPS Investment Partners, a subsidiary of BlackRock, Inc., to manage and operate its CenterWell Senior Primary Care clinic network. This arrangement replaces CenterWell's existing joint venture with Welsh, Carson, Anderson & Stowe (WCAS), with BlackRock acquiring WCAS's equity stake under modified terms. Notably, the new JV eliminates the previous put option held by WCAS, resulting in an expected significant reduction in balance sheet liabilities and a lower overall cost of capital. Concurrently, Humana reaffirmed its FY 2026 Adjusted EPS guidance of at least $9.00.
The transaction removes a substantial put option liability from Humana's balance sheet, lowers the cost of capital for its CenterWell care delivery expansion, and de-risks capital allocation while reaffirming 2026 earnings expectations.
Track Humana Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your free Explorer workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- BlackRock subsidiary HPS Investment Partners acquired WCAS's equity stake in CenterWell Senior Primary Care clinics under a restructured joint venture eliminating previous put option liabilities.
- CenterWell secures the option to purchase clinics starting in 2028, with BlackRock holding exit rights via a sale process by end-2033 if clinics remain unacquired.
- Humana reaffirmed its full-year 2026 Adjusted EPS guidance of at least $9.00 per common share.
Connected Companies & Entities
1 Entity mappedRelated Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
8-K Financial Filing Analysis for Humana (2026-09-01)
On September 1, 2026, Humana Inc. filed a Form 8-K announcing that senior management will reaffirm the company's full-year 2026 financial guidance during upcoming investor and analyst conferences throughout September. Humana continues to project full-year 2026 diluted GAAP EPS of at least $6.52 and non-GAAP Adjusted EPS of at least $9.00, maintaining the outlook originally issued on July 29, 2026. Furthermore, the company clarified that it will withhold commentary regarding the 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028) until final data is officially published by the Centers for Medicare and Medicaid Services (CMS) in October.
8-K Financial Filing Analysis for Humana (2026-10-09)
Humana Inc. announced that it has exceeded its goal of Top Quartile results for the 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028), based on final data released by the Centers for Medicare and Medicaid Services (CMS) on October 8, 2026. Top Quartile performance is defined as Stars revenue per member per month (PMPM) at least 10% above the peer group median. While anticipating that a portion of the 2028 bonus outperformance will be one-time in nature, Humana expects to utilize the resulting financial benefit for one-time investments and capital returns to shareholders. Concurrently, the company reaffirmed its full-year 2026 Adjusted EPS guidance of at least $9.00 and announced a virtual investor update scheduled for December 10, 2026.
Hawesko Cuts 2026 Guidance After Weak Quarter
Hawesko Holding SE lowered its 2026 financial guidance after weaker-than-expected July and third-quarter developments and only limited seasonal pickup expected. Revenue is now forecast to fall 2–4% year-on-year (previously up to +2%). Operating EBIT before one-offs is guided to €23–26m (previously €28–32m). One-off charges may reach up to €4m (previously max. €2m). Free cash flow guidance was reduced to €28–33m (previously €30–36m) and ROCE is now expected at 9–11% (previously 11–14%). In H1 2026 Hawesko reported revenues of €274.8m (down 3.6% from €285.1m), an improved gross margin (43.9% → 45.2%) and operating EBIT decline from €6.1m to €5.1m. Management plans to intensify the FOKUS efficiency program and transform its e-commerce operations starting in autumn.
Receive all future signals for Humana & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.